New Delhi, Apr 11 (PTI) Morepen Laboratories on Friday said it will add more than 1,000 medical representatives over the next three years, with over 200 team members expected to join in FY26 alone.

The company aims to strengthen its formulations business in the market through new hirings.

Also Read | What Is Rajiv Yuva Vikasam Scheme? How To Apply for It? All You Need To Know About Telangana Govt's Flagship Initiative To Provide Financial Assistance up to INR 4 Lakh to Unemployed Youth.

"This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domestic finished dosage market," Morepen Laboratories Chairman and MD Sushil Suri said in a statement.

With significant increase in the sales force and enhanced reach to doctors, pharmacies, and patients, the drugmaker is setting the stage for getting a bigger pie in the Indian pharmaceutical market valued at Rs 2.38 lakh crore, yielding higher gross margins and better returns for stakeholders in the long run, he added.

Also Read | Bodoland Lottery Result Today, April 11, 2025: Assam State Lottery Sambad Friday Lucky Draw Results Declared, Check Winners List With Ticket Numbers.

Currently, Morepen's formulation business stands around Rs 325 crore, and the company is targeting to touch Rs 1,000 crore in the next five years.

This goal will be supported by an aggressive expansion of the medical representative network and deeper market penetration across urban and rural India, with major growth expected from new products that the company is already producing at highly competitive costs, the company said.

The Indian pharmaceutical market is projected to reach USD 130 billion in 2030, with an expected annual growth rate of 8.2 per cent.

Morepen shares were trading 3.84 per cent up at Rs 49.97 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)